Abstract
Enterococcal bacteremia is associated with high mortality and long-term hospitalization. Here, we aimed to investigate the clinical outcomes and evaluate risk factors for mortality in adult patients treated with vancomycin (VCM) for penicillin-resistant Enterococcus faecium (E. faecium) bacteremia. Data were collected from inpatients at a single university hospital between January 2009 and December 2020. The area under the curve (AUC) of VCM was calculated using the Bayesian approach. The primary outcome was 30-day in-hospital mortality. Univariate analysis showed significant differences in the combined use of vasopressors, history of the use of inactive antimicrobial agents against E. faecium, VCM plasma trough concentration, and renal dysfunction during VCM administration between 30-day mortality and survival groups. However, the AUC/minimum inhibitory concentration (MIC) was not significantly different. Multivariate analysis revealed that concomitant vasopressors were an independent risk factor for 30-day all-cause mortality (odds risk, 7.81; 95% confidence interval, 1.16–52.9; P = 0.035). VCM plasma trough concentrations and AUC/MIC in the mortality group were higher than those in the surviving group. Depending on the drug-susceptibility results of E. faecium, it is considered that the AUC/MIC is calculated at a double AUC value. No association between AUC/MIC and treatment effect in E. faecium bacteremia was assumed because the known target AUC/MIC was sufficiently achieved in the mortality group. When an immunocompromised host develops E. faecium bacteremia with septic shock, especially in situations where the hemodynamics of using a pressor agent is unstable, treating it exclusively by sufficient exposure to antibacterial agents may be difficult.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the guidelines of the Helsinki declaration, and the protocol was approved by the ethics committee of Juntendo university hospital (approval no. 20-270).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
